What the FDA labels say about taking them together
Nelfinavir and nimodipine
Nimodipine's FDA label of August 30, 2024 names nelfinavir in its drug interactions section; nelfinavir's label does not name nimodipine itself but warns about its class (Calcium channel blockers (dihydropyridines)). The nimodipine label: “Risk of Hypotension with Strong CYP3A4 Inhibitors Concomitant use of strong inhibitors of CYP3A4, such as some macrolide antibiotics, some HIV protease inhibitors, some HCV protease inhibitors, some azole antimycotics …”
Check it at the source: the nelfinavir FDA label on DailyMed (effective December 11, 2025, AGOURON); the nimodipine FDA label on DailyMed (effective August 30, 2024, Azurity Pharmaceuticals, Inc.).
What does the nelfinavir label say about nimodipine?
Nelfinavir's label does not name nimodipine itself; it warns about its class (Calcium channel blockers (dihydropyridines)):
Nelfinavir label, drug interactionsCoadministration of VIRACEPT and drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers, HMG-CoA reductase inhibitors, immunosuppressants, and PDE5 inhibitors) may result in increased plasma concentrations of such drugs that could increase or prolong both its therapeutic and adverse effects (see Tables 3 and 6 ).
Source: FDA drug label (VIRACEPT), AGOURON, effective December 11, 2025 (SPL set e72c2bc6-9462-4a2e-8e1d-b97592376cbd), via openFDA; the full label on DailyMed
What does the nimodipine label say about nelfinavir?
Nimodipine label, drug interactionsStrong CYP3A4 inhibitors include some members of the following classes: macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, saquinavir), HCV protease inhibitors (e.g., boceprevir, telaprevir), azole antimycotics (e.g., ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan, delavirdine, nefazodone Nimodipine plasma concentration can also be increased in the presence of moderate and weak inhibitors of CYP3A4.
Nimodipine label, warnings and precautionsRisk of Hypotension with Strong CYP3A4 Inhibitors Concomitant use of strong inhibitors of CYP3A4, such as some macrolide antibiotics (e.g., clarithromycin, telithromycin), some HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, saquinavir), some HCV protease inhibitors (e.g., boceprevir, telaprevir), some azole antimycotics (e.g., ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan, delavirdine, and nefazodone with nimodipine should generally be avoided because of a risk of significant hypotension [see Drug Interactions (7.2) ].
Source: FDA drug label (Nymalize), Azurity Pharmaceuticals, Inc., effective August 30, 2024 (SPL set e660fa26-b5c4-4d6d-8887-9e22b6666a10), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nelfinavir | Nimodipine | |
|---|---|---|
| Labeled for | HIV | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $1.37 per capsule 30 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once